Ir arriba

CELL THERAPY FROM THE BENCH TO THE BEDSIDE AND RETURN

Fechas y lugar de celebración

  • Fechas de realización: Del 08-07-2019 al 12-07-2019
  • Sede: LOS ALCÁZARES
  • Lugar: Hotel 525. C/ del Río Borines, 58. Los Alcázares, Murcia. Spain.

Plazos

  • Inscripción: Del 20/02/2019 al 03/07/2019

Objetivos

The aim of this course is the diffusion of knowledge about stem cells and their therapeutic possibilities, with a special emphasis on Hematopoietic Stem Cell Transplants and Regenerative Medicine.

The course is intended to provide a forum for scientific discussion with basic researchers and clinical experts in cell therapy, and to set out the achievements and challenges in this exciting new area of Medicine.

Specific Course Objectives are:

To analyse in depth the different types of stem cells, their biological properties, their laboratory manipulation and their clinical use.

To learn the new types of hematopoietic cell transplantation, and new approaches of immune modulation.

To discuss the present clinical trials of stem cell therapy for repairing organs and tissues.

Organización de la actividad

Dirección

  • Prof. JOSÉ MARÍA MORALEDA JIMÉNEZ
  • Prof. DAMIÁN GARCÍA OLMO
  • Prof. ROBERT SACKSTEIN
  • Prof. SALVADOR MARTÍNEZ PÉREZ

Destinado a

Students, graduates and others interested in the subject

Datos generales

  • Duración: 30 horas
  • Número máximo de alumnos: 100
  • Créditos CRAU: 1.0

Precios

  • Precio público: 160 € Luch included

Programa

Lunes 8 BONE MARROW STEM CELLS. HEMATOPOIETIC STEM CELL TRANSPLANTION. Chair: Prof. José M. Moraleda. Professor of Medicine. IMIB-Arrixaca. University of Murcia, Spain.

  • 09:00 h. Open Session.
    • Hon. Mr. José Luján Alcaraz
      Rector of the University of Murcia. Murcia, Spain.
    • Hon. Mr. Manuel Villegas García
      Health Council of the Autonomous Community of the Region of Murcia. Murcia, Spain.
    • Prof. José María Moraleda Jiménez
    • Prof. Robert Sackstein
  • 09:30 h. The Biology of the Hematopoietic Stem Cell.
    • Prof. Agustín Zapata González
      Professor of Cell Biology. Complutense University of Madrid. Madrid, Spain.
  • 10:00 h. Procurement of Hematopoietic Progenitors: Cellular Selection.
    • Prof. Miguel Blanquer Blanquer
      Hematology Department, Institute Research IMIB-Arrixaca, Virgen de la Arrixaca University Hospital. University of Murcia. Murcia, Spain.
  • 10:30 h. Hematopoietic cell transplantation: cell therapy to cure haematological diseases.
    • Prof. José María Moraleda Jiménez
      Professor of Medicine. University of Murcia. Head Dpt. of hematology and HSCT Program. Institute of Biomedical Research of Murcia - IMIB, Vigen de la Arrixaca University Hospital. Murcia, Spain.
  • 11:00 h. Coffee Break.
  • 11:30 h. The HLA system,T cells, APC, NK cells. Understanding the immune system.
    • Prof. Alejandro Madrigal Fernández
      Scientific Director of The Anthony Nolan Trust. Chair of Hematology. The Royal Free and University College Medical School. London, UK.
  • 12:00 h. Graft versus host disease and GVL. The Jekyl and Hyde of allotransplantation.
    • Prof. José Antonio Pérez Simón
      Professor of Hematology. Head Hematology Department. Institute of Biomedicine, Virgen del Rocío University Hospital. University of Sevilla. Sevilla, Spain.
  • 12:30 h. Haploidentical transplants. Past, present and future.
    • Prof. Fabio Ciceri
      Department of Hematology. IRCCS Ospedale San Raffaele. Vita-Salute San Raffaele. Milan, Italy.
  • 13:30 h. Lunch.
  • 15:00 h. Natural killer cell therapy for pediatric solid tumors: from the bench to the bedside and back to the bench.
    • Prof. Antonio Pérez Martínez
      Head Department of Pediatric Hematology. University Hospital La Paz. Madrid, Spain.
  • 15:30 h. Hematopoietic Stem Cell transplantation. The way to cure HIV?
    • Prof. Rafael Duarte Palomino
      Head Clinical Hematology. University Hospital Puerta de Hierro. Madrid, Spain.
  • 16:00 h. Debate session: Umbilical cord banks use.
    • What is an umbilical cord blood bank. Mission and perspectives.
      Prof. Sergi Querol Giner. Director Banc de Sang y Teixits. Barcelona, Spain.
    • The Spanish UCB plan.
      Prof. Jorge Gayoso Cruz. Medical Associate. National Transplant Organization (ONT). Madrid, Spain.
    • Sustainability of academic facilities procuring and processing human cells for therapeutic use.
      Prof. Christian Chabannon. Professor of Cell Biology. Aix Marseille University. Chair EBMT Cell Therapy & IB WP. France.
    • Chair: Prof. Alejandro Madrigal Fernández
      Scientific Director of The Anthony Nolan Trust. Chair of Hematology. The Royal Free and University College Medical School. London, UK.

Martes 9 IMMUNE EFFECTOR CELL APPROACHES TO CURE CANCER. Chair: Prof. Robert Sackstein. Senior VP for Health Affairs and Dean, Herbert Wertheim College of Medicine Florida International University, USA.

  • 09:00 h. CAR-T cells. Basic principles and clinical Pharmacology.
    • Prof. Irene García Cadenas
      Hematology Dpt. Hospital Sant Pau. Institut Josep Carreras. University of Barcelona. Barcelona, Spain.
  • 09:30 h. Novartis CAR-T cells manufacture and results in leukemia and lymphoma. What is next?
    • Dra. Mónica Jiménez Hernández
      Therapeutical Area Manager. Novartis. Barcelona, Spain.
  • 09:50 h. Kite in the future of CAR-T cell therapy.
    • Dra. Margarida Pallá García
      Medical Manager Cell Therapy, Oncology Gilead Scienses. Madrid, Spain.
  • 10:10 h. Celgene CAR-T cells manufacture and results in myeloma. What is next?
    • Dra. Marta Durán Delmàs
      Associate Medical Director. Celgene. Madrid, Spain.
  • 10:30 h. Advanced cell therapy manufacture. The Miltenyi Biotec approach.
    • Dr. José Luis Mateos Sanz
      Clinical Business Manager. MiltenyiBiotec. Madrid, Spain.
  • 10:50 h. Coffee Break.
  • 11:20 h. CAR-T cells against solid tumours.
    • Prof. Sònia Guedán Carrió
      Hospital Clinic. Institut Josep Carreras. University of Barcelona. Barcelona, Spain.
  • 11:50 h. CAR-T cells in academic centres. The experience of the Hospital Clinic.
    • Prof. Álvaro Urbano-Ispizua
      Hospital Clinic. Institut Josep Carreras. University of Barcelona. Barcelona, Spain.
  • 12:20 h. CAR-T CD44v6 against acute myeloid leukemia and multiple myeloma.
    • Prof. Fabio Ciceri
      Department of Hematology. IRCCS Ospedale San Raffaele. Vita-Salute San Raffaele. Milan, Italy.
  • 12:50 h. The future of Immune Effector cell therapy (IET). Do we need standards? Does the regulation of IET affect the practice of SCT?
    • Prof. Christian Chabannon
      Professor of Cell Biology. Aix Marseille University. Chair EBMT Cell Therapy & IB WP. France.
  • 13:20 h. Lunch.
  • 15:00 h. CAR-T cells for Hodgkin's lymphoma.
    • Prof. Javier Briones Meijide
      Hematology Dpt. Hospital Sant Pau. Institut Josep Carreras. University of Barcelona. Barcelona, Spain.
  • 15:30 h. Glycoengineering CAR-T cells. Improving delivery to bone marrow.
    • Prof. Robert Sackstein
      Senior VP for Health Affairs & Dean, Herbert Wertheim College of Medicine Florida International University. Miami. FL, USA.
  • 16:00 h. Debate session: Are we going to cure cancer with CAR-T cells?
    • Chair: Prof. José María Moraleda Jiménez
    • Prof. Robert Sackstein
    • Prof. Fabio Ciceri
    • Prof. Christian Chabannon
    • Prof. Sònia Guedán Carrió

Miércoles 10 MESENCHYMAL STEM CELLS (MSC), INDUCED PLURIPOTENT STEM CELLS (iPSC), GENE THERAPY: SCIENTIFIC BASIS FOR ITS THERAPEUTIC USE. Chair: Prof. José M. Moraleda. Professor of Medicine. IMIB-Arrixaca. University of Murcia, Spain.

  • 09:00 h. MSC properties: the biological basis to become a cell medicine.
    • Prof. Agustín Zapata González
      Professor of Cell Biology. Complutense University of Madrid. Madrid, Spain.
  • 09:30 h. The extrinsic regulation of haematopoietic stem cells as a therapeutic target.
    • Prof. Simón Méndez-Ferrer
      Department of Haematology, NHS-Blood and Transplant. Cambridge Biomedical Campus. University of Cambridge. Cambridge, UK.
  • 10:00 h. Fucosylated mesenchymal stem cells to establish tissue immunohomeostasis.
    • Prof. David García Bernal
      Cell Therapy Unit and HSCT Program. Institute of Biomedical Research of Murcia - IMIB, Virgen de la Arrixaca University Hospital. University of Murcia. Murcia, Spain.
  • 10:30 h. Coffee Break.
  • 11:00 h. Gene Therapy for Fanconi anemia.
    • Prof. Juan Antonio Bueren Roncero
      Hematopoietic Innovative Therapies Division. CIEMAT. University of Madrid. Madrid, Spain.
  • 11:30 h. Gene Therapy for Haemophilia: the new road to cure Hemophilia.
    • Prof. María Eva Mingot Castellano
      Associate Professor. University of Málaga. Hematology Department. University Hospital. Málaga, Spain.
  • 12:00 h. iPSC as a Therapeutic Tool.
    • Prof. Ángel Raya Chamorro
      Director Center of Regenerative Medicine in Barcelona (CMRB). Barcelona, Spain.
  • 13:00 h. Lunch.
  • 14:30 h. Microvesicles: the new therapeutic weapon from the MSC.
    • Prof. Fermín Sánchez-Guijo Martín
      Professor of Hematology. Hematology Department. University Hospital of Salamanca. Salamanca, Spain.
  • 15:00 h. Production of cells and tissues in GMP facilities: a real challenge.
    • Prof. María Eugenia Fernández Santos
      Technical Director of the Cell Production Unit. Gregorio Marañón University Hospital. Institute Gregorio Marañón. Madrid, Spain.
  • 15:30 h. The future of the University in Spain. Just a finance problem?
    • Prof. José Antonio Cascales Saseta
      Managing Director. University of Murcia. Murcia, Spain.

Jueves 11 CELL THERAPY AND TISSUE ENGINEERING. CLINICAL TRIALS. Chairs: Prof. Damián García-Olmo. Professor of Surgery. Autonomous University of Madrid, Spain and Prof. José M. Moraleda. Professor of Medicine.IMIB-Arrixaca. University of Murcia, Spain

  • 09:00 h. Cell Therapy and tissue engineering in Cardiac Diseases.
    • Prof. Felipe Prósper Cardoso
      Director of Cell Therapy Department. Co-director Hematology Department. University of Navarra. Navarra, Spain.
  • 09:30 h. Cell Therapy in Diabetes Mellitus.
    • Prof. Bernat Soria Escoms
      Professor of Physiology. University Pablo de Olavide. Sevilla, Spain.
  • 10:00 h. Cell Therapy for Osteoarticular Repair.
    • Prof. Javier García-Sancho Martín
      Professor of Physiology. School of Medicine. Institute of Biology and Molecular Genetics (IBGM). University of Valladolid. Valladolid, Spain.
  • 10:30 h. Coffee Break.
  • 11:00 h. Regenerative Medicine for high level athletes. Epigenetic models of the treatment of degenerative condrocytes.
    • Prof. Pedro Guillén García
      Professor of Traumatology. Clinical Research Unit, CEMTRO Hospital. Madrid, Spain.
  • 11:30 h. Cell Therapy and tissue bioengineering in Odontology.
    • Prof. Francisco Javier Rodríguez Lozano
      Professor of Dentistry. Institute of Biomedical Research IMIB-Arrixaca. Virgen de la Arrixaca University Hospital. University of Murcia. Murcia, Spain.
  • 12:00 h. Cell Therapy in Surgery. The road map to success. What is next?
    • Prof. Damián García Olmo
      Professor of Surgery. Chief of Departament of Surgery. Fundación Jiménez Díaz University Hospital. Autonomus University of Madrid. Madrid, Spain.
  • 13:00 h. Lunch.
  • 14:30 h. Debate session: Stem cell information and the benefits and dangers of the social media. How to combat the stem cell therapy fraud.
    • The role of TerCel good clinical practice committee.
      Prof. Ramón Muñoz Chapuli. Professor of Medicine. University of Málaga. Coordinator Good clinical Practice Commettee. TerCel. Málaga, Spain.
    • The role of social media.
      Prof. Juan Tomás Frutos. Professor of journalism. Head of TV1 news in Murcia. University of Murcia. Murcia, Spain.
    • The role of patients associations on access to CAR-T: How to manage the hype.
      Prof. Natacha Bolaños Martínez. Patient association. Lymphoma Coalition. Madrid, Spain.
    • The role of the Spanish Agency of medicines and health products (AEMPS).
      Prof. Sol Ruiz Antúnez. Head of the Unit of Biotechnology and Advanced Therapies at EMA. AEMPS. Madrid, Spain.
    • Chair: Prof. Agustín Zapata González
      Professor of Cell Biology. Complutense University of Madrid. Madrid, Spain.

Viernes 12 CELL THERAPY IN NEUROLOGICAL DISEASES. Chair: Prof. Salvador Martínez Pérez. Director Institute of Neurosciences. UMH-CSIC. Professor of Human Anatomy and Embryology. University Miguel Hernández. Elche, Spain

  • 09:30 h. Is there any place for Cell therapy in Parkinson's disease?
    • Prof. José Luis Labandeira García
      Professor of Human Anatomy and Embriology. Center for Research in molecular medicine (CiMUS). Director Dpt. Morphological Sciences. University of Santiago de Compostela. A Coruña, Spain.
  • 10:00 h. Antiparkinsonian cell therapy using carotid body cells.
    • Prof. Juan José Toledo Aral
      Professor of Physiology. Director of the Dpt. of Medical Physiology and Biophysics. Institute of Biomedical Research of Seville. IBiS, Virgen del Rocio Hospital/CSIC/University of Sevilla. Sevilla, Spain.
  • 10:30 h. Coffee Break.
  • 11:00 h. Cell therapy for Amyotrophic Lateral Sclerosis. New developments.
    • Prof. Salvador Martínez Pérez
      Director Institute of Neurosciences. UMH-CSIC. Professor of Human Anatomy and Embryology. University Miguel Hernández. Alicante, Spain.
  • 11:30 h. Cell Therapy to cure glioblastoma. Preclinical studies and clinical insights.
    • Prof. Rut Valdor Alonso
      Cell Therapy Unit and HSCT Program. Institute of Biomedical Research of Murcia - IMIB, Virgen de la Arrixaca University Hospital. University of Murcia. Murcia, Spain.
  • 12:00 h. Key question conference: clues for improving translational research in Spain.
    • Prof. Joan Comella
      Director Research Institute Vall d'Hebron. Professor of Histology Universitat Autònoma de Barcelona. Barcelona, Spain.
  • 13:00 h. Lunch.
  • 14:30 h. Special Talks: Science and other matters of life.
    • Does our brain work properly to heal us? My particular odyssey.
      Prof. Jose Sebastian Carrion Garcia. Professor of Evolutive Biology. University of Murcia. Murcia, Spain.
    • The Spanish Science system. My vision to get the system working.
      Prof. Cristobal Belda Iniesta. Deputy Director of Evaluation and Promotion of Research of the Carlos III Health Institute (ISCIII. Madrid, Spain.
    • Chair: Prof. José María Moraleda Jiménez
      Professor of Medicine. University of Murcia. Head Dpt. of hematology and HSCT Program. Institute of Biomedical Research of Murcia - IMIB, Vigen de la Arrixaca University Hospital. Murcia, Spain.
  • 16:00 h. Closing ceremony and awarding of certificates.

Aclaraciones

The Course has been declared of Scientific and Medical Interest by the Public Health System of Murcia.

Colaboradores

S.E.H.H.
S.E.H.H.

Instituto de Salud Carlos III
Instituto de Salud Carlos III

Red Tercel
Red Tercel

AMGEN
AMGEN

MSD
MSD

Gilead
Gilead

Janssen
Janssen

MACS Miltenyi Biotec
MACS Miltenyi Biotec

Celgene
Celgene

Pfizer
Pfizer

SANOFI
SANOFI

TAKEDA
TAKEDA

abbvie
abbvie

Sandoz Farmaceutica
Sandoz Farmaceutica

Novartis
Novartis

Jazz Pharmaceuticals
Jazz Pharmaceuticals

Kern Pharma
Kern Pharma

novo nordisk
novo nordisk

Techdow
Techdow